First-in-Humans Study of Third GlycoMimetics Drug Candidate
ROCKVILLE, MD, USA I September 6, 2016 I GlycoMimetics, Inc. (NASDAQ: GLYC) today announced dosing of the first healthy volunteers in a new Phase 1 clinical trial evaluating its novel combined E-selectin and CXCR4 antagonist GMI-1359. In this first-in-humans trial, volunteer participants will receive a single injection of GMI-1359, which will be evaluated for safety, tolerability, pharmacokinetics and pharmacodynamics. GlycoMimetics intends to develop GMI-1359 as a potential treatment for hematologic malignancies.
“Our preclinical data points to the potential of GMI-1359 to inhibit the growth and metastasis of a variety of cancers. We believe this is due to a novel mechanism of action provided by inhibiting both E-selectin and CXCR4 simultaneously,” said Helen Thackray, M.D., Chief Medical Officer of GlycoMimetics. “This first clinical trial will position the program for further development in hematologic malignancies and other cancers.”
The randomized, double-blind escalating dose study is being conducted at a single site in the United States. Each volunteer will receive a single dose of GMI-1359, and participate for 16 days of evaluation during the trial.
Previous preclinical research has been shared via oral and poster presentations at the annual meetings of both the American Association for Cancer Research Annual and the American Society of Hematology. Data presented have demonstrated activity in models of acute myelogenous leukemia (AML), prostate cancer and pancreatic cancer.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics’ most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics’ wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML . GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
SOURCE: GlycoMimetics
Post Views: 81
First-in-Humans Study of Third GlycoMimetics Drug Candidate
ROCKVILLE, MD, USA I September 6, 2016 I GlycoMimetics, Inc. (NASDAQ: GLYC) today announced dosing of the first healthy volunteers in a new Phase 1 clinical trial evaluating its novel combined E-selectin and CXCR4 antagonist GMI-1359. In this first-in-humans trial, volunteer participants will receive a single injection of GMI-1359, which will be evaluated for safety, tolerability, pharmacokinetics and pharmacodynamics. GlycoMimetics intends to develop GMI-1359 as a potential treatment for hematologic malignancies.
“Our preclinical data points to the potential of GMI-1359 to inhibit the growth and metastasis of a variety of cancers. We believe this is due to a novel mechanism of action provided by inhibiting both E-selectin and CXCR4 simultaneously,” said Helen Thackray, M.D., Chief Medical Officer of GlycoMimetics. “This first clinical trial will position the program for further development in hematologic malignancies and other cancers.”
The randomized, double-blind escalating dose study is being conducted at a single site in the United States. Each volunteer will receive a single dose of GMI-1359, and participate for 16 days of evaluation during the trial.
Previous preclinical research has been shared via oral and poster presentations at the annual meetings of both the American Association for Cancer Research Annual and the American Society of Hematology. Data presented have demonstrated activity in models of acute myelogenous leukemia (AML), prostate cancer and pancreatic cancer.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics’ most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics’ wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML . GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
SOURCE: GlycoMimetics
Post Views: 81
